C
메디톡스
086900KOSDAQ기초 의약물질 제조업43.3 / 100
Reference Date: 2026-04-13
Financial Score18.5 / 40
News Sentiment11.8 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is low with sound financial health but Operating Profit metrics are weak. Declined 13.8% over the past month, and news sentiment is negative.
Company InformationBased on 2025 Annual Report
Business Overview
Medytox specializes in the research, development, manufacturing, and sales of biopharmaceuticals using botulinum toxin type A, with flagship products such as Meditoxin® and Innotox®. In 2024, its key pharmaceutical products accounted for approximately 84% of consolidated revenue, and the company has expanded exports to over 30 countries.
Number of Employees
753people
Average Salary
64.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
42.98Industry Average 33.453.0Point
Higher than industry avg (caution)
PBR
1.64Industry Average 2.034.0Point
In line with industry avg
ROE
3.39Industry Average -4.293.5Point
Well below industry avg
Debt Ratio
4.99Industry Average 6.614.0Point
In line with industry avg
Trend 2023~20254.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲5.8% (2-year basis)
Operating Profit Growth Rate
1.0 / 3
Avg ▲0.5% (2-year basis)
ROE Trend
1.0 / 4
Avg ROE 3.0% (improving, 3yr)
Detailed News Sentiment
11 totalPositive 0Neutral 4Negative 2Average Sentiment Score 45
- Neutral
- Neutral
- Neutral
Detailed Momentum
52-week position1.0Point
Near 52w low (5%, downtrend)
Current 101,900Won52-week high 181,60052-week low 97,400
1-month return1.0Point
1m -13.79% (falling)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
6 totalPositive 0Neutral 6Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-04-02
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-02
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
- Neutral정기주주총회결과2026-03-27
- Neutral사업보고서 (2025.12)2026-03-19